China ATTR (Transthyretin Amyloidosis) Therapeutics Market Size and Share 2023 | Upcoming Trends, Development Status and in-Depth Analysis Research Report by 2028

Report Overview

The China ATTR (Transthyretin Amyloidosis) Therapeutics market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

The diagnosis and treatment of rare diseases are an important public health issue and a challenge for medical care in China. The prevalence rate of ATTR (Transthyretin Amyloidosis) disease in China is 1997 people per 1,00,000. With its enormous population, disparate geography and socioeconomic inequalities, China faces considerable obstacles in improving the standard of care for patients who are affected by ATTR (Transthyretin Amyloidosis) disease.

Market Drivers

China is the growing market for ATTR (Transthyretin Amyloidosis) disease due to enormous population and increasing aging population leads to increase in Chinas Prevalence rate 1997 people per 1,00,000. Faster adaptation to healthcare technology, various government policies such as investing in the R&D for developing the new treatment methods, prioritized approval process by China FDA, research funding in rare diseases, tax reduction, collaboration with international communities, Reimbursement policies, and government awareness programs are leading to growth of ATTR (Transthyretin Amyloidosis) therapeutics.

There are some restraining factors for growth of ATTR (Transthyretin Amyloidosis) therapeutics market in China such as absence of official legislation, high rate of misdiagnosis and limited funding for high-cost drugs.

Get PDF Sample Report Now! @ https://www.prudentmarkets.com/sample-request/139784/

Major Players

Some of the key players in the ATTR (Transthyretin amyloidosis) therapeutics market are Pfizer Inc.; Ionis Pharmaceuticals inc.; Alnylam Pharmaceuticals Inc.;

Key players are adopting various strategies such as strategic collaboration to increase their market share and also to develop new therapy for effective treatment of the disease. For instance, Alnylam and Genzyme (a Sanofi company) form alliance to develop and commercialize RNAi therapeutics targeting transthyretin (TTR) for the treatment of transthyretin mediated amyloidosis in Asia-Pacific countries (China).

Product pipeline of Alnylam Pharmaceuticals Inc. - Vutrisiran (in Phase 2-Phase 3 development).

The China ATTR (Transthyretin Amyloidosis) Therapeutics Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global China ATTR (Transthyretin Amyloidosis) Therapeutics market. This report explores all the key factors affecting the growth of the global China ATTR (Transthyretin Amyloidosis) Therapeutics market, including demand-supply scenario, pricing structure, profit margins, production, and value chain analysis.

To Know More About COVID-19 Impact On China ATTR (Transthyretin Amyloidosis) Therapeutics Market @ https://www.prudentmarkets.com/sample-request/139784/

Market Segmentation

By Drug Type:

On the basis of the drug Type, the China ATTR (Transthyretin Amyloidosis) therapeutics market is segmented into transthyretin stabilizers, nonsteroidal anti-inflammatory drugs, therapeutic antisense oligonucleotides and monoclonal antibodies.

Transthyretin Stabilizers include drugs such as Tafamidis and Epigallocatechin-3-gallate. Nonsteroidal Anti-Inflammatory Drugs are used to control the symptoms associated with the disease and it include drug such as Diflunisal. Therapeutic antisense oligonucleotides consist of Inotersen. Monoclonal antibodies are also used for the treatment it includes Dezamizumab.

By Distribution Channel:

Based on the distribution channel, the China ATTR (Transthyretin Amyloidosis) therapeutics market has been segmented into hospitals, retail, online pharmacies. During the forecast period (2019-2028) hospital pharmacies is the key distribution channel segment of the ATTR (Transthyretin Amyloidosis) therapeutics market. Clinical examination and supporting laboratory investigations for the diagnosis of ATTR (Transthyretin Amyloidosis) are best possible in hospitals. Retail and online pharmacies are the second largest distribution channels.

By Indication:

On the basis of the indication, the China ATTR (Transthyretin Amyloidosis) therapeutics market is segmented into wild type ATTR amyloidosis and hereditary ATTR amyloidosis.

Wild Type ATTR Amyloidosis: Wild type does not involve abnormal DNA and cannot be passed onto family members. Instead, as you get older, the normal TTR protein becomes unstable, misfolds and forms amyloid fibrils.

Hereditary ATTR Amyloidosis: In this form, there is a change in the DNA that is inherited and can be passed from one generation to the next. This makes the TTR protein more unstable and more likely to form amyloid fibrils. In this type genetic mutation prevents TTR protein, which is made in the liver, from having its normal structure. Instead TTR misfolds and accumulates as amyloid deposits in the body (heart, nerves, GI tract) causing debilitating symptoms.

 

Major Players

Some of the key players in the ATTR (Transthyretin amyloidosis) therapeutics market are Pfizer Inc.; Ionis Pharmaceuticals inc.; Alnylam Pharmaceuticals Inc.;

Key players are adopting various strategies such as strategic collaboration to increase their market share and also to develop new therapy for effective treatment of the disease. For instance, Alnylam and Genzyme (a Sanofi company) form alliance to develop and commercialize RNAi therapeutics targeting transthyretin (TTR) for the treatment of transthyretin mediated amyloidosis in Asia-Pacific countries (China).

Product pipeline of Alnylam Pharmaceuticals Inc. - Vutrisiran (in Phase 2-Phase 3 development).

Prudent Markets provides attractive discounts that fit your needs. Customization of the reports as per your requirement is also offered. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Speak To Our Analyst For A Discussion On The Above Findings, And Ask For A Discount On The Report @ https://www.prudentmarkets.com/discount-request/139784/

The report covers the competitive analysis of the market. As the demand is driven by a buyer's paying capacity and the rate of item development, the report shows the important regions that will direct growth. This section exclusively shares insight into the budget reports of big-league members of the market helping key players and new entrants understand the potential of investments in the Global China ATTR (Transthyretin Amyloidosis) Therapeutics Market. It can be better employed by both traditional and new players in the industry for complete know-how of the market.

Strategic Points Covered in Table of Content of Global China ATTR (Transthyretin Amyloidosis) Therapeutics Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the China ATTR (Transthyretin Amyloidosis) Therapeutics market
Chapter 2: Exclusive Summary - the basic information of the China ATTR (Transthyretin Amyloidosis) Therapeutics Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the China ATTR (Transthyretin Amyloidosis) Therapeutics
Chapter 4: Presenting the China ATTR (Transthyretin Amyloidosis) Therapeutics Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the China ATTR (Transthyretin Amyloidosis) Therapeutics market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Any Questions? Feel Free To Enquire Here. We Will put you on the Right Path @ https://www.prudentmarkets.com/enquiry-request/139784/

Free Customization on the basis of client requirements on Immediate purchase:
1- Free country-level breakdown of any 5 countries of your interest.
2- Competitive breakdown of segment revenue by market players.

Customization of the Report:
This report can be customized to meet the client's requirements. Please connect with our sales team (sales@prudentmarkets.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +91 83560 50278 || USA/Canada(Toll Free): 1800-601-6071 to share your research requirements.

Get ready to Recognize the pros and cons of the regulatory framework, local reforms, and its effect on the Industry. Understand how the Leaders in Intelligent Network are keeping themselves one stage forward with our most up-to-date survey analysis.

In conclusion, the China ATTR (Transthyretin Amyloidosis) Therapeutics Market report is a genuine source for accessing the research data which is projected to exponentially grow your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis and PESTLE analysis is also incorporated in the report.

Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: sales@prudentmarkets.com
Web: www.prudentmarkets.com

About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.

This release was published on openPR.